About The Report. imarc. Key Questions Answered in this Report:

Transcription

1

2 About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise. IMARC s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3 About The Report IMARC s new report Canada Diabetes Market Report & Forecast provides an analytical and statistical insight into the Canadian diabetes market. The report provides both current and future trends in the prevalence and demographical breakup of diabetes in Canada. The report has segmented the Canada diabetes market into two segments Insulin and the Oral Antidiabetics market. For each of the aforementioned categories, the report provides historical and future market sales of key classes, key companies, key drugs and key molecules. The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the Canadian diabetes market till This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Canadian diabetes market in some form or the other. Key Questions Answered in this Report: What is the size and demographical breakup of the diabetes population in Canada? How has the diabetes market behaved since 2005 and what are the expected trends till 2016? What has been the historical performance of the Canadian Insulin market during and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during ? What has been the historical performance of the Oral Antidiabetics market during and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during ?

4 Why should you buy this report? Gain a deeper understanding about the prevalence of diabetes in Canada and identify your potential patient pool. Analyze the historical, current and future trends in the Insulin and Oral Antidiabetic markets and identify potential classes, drugs, partners and competitors for market entry and expansion plans. Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Canadian Insulin and Oral Antidiabetic markets. Gain an insight into future market events such as biosimilars and new product launches. Classes Covered: Fast acting Insulin, Long acting Insulin, Intermediate and Fast acting Insulin, Intermediate acting Insulin, Biguanides, Glitazone and Biguanide Combinations, Biguanide and Sulphonylurea Combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide Combinations, DPP-IV Inhibitor and Glitazone Combinations, Glitazone and Sulphonylurea Combinations, SGLT Inhibitors, SGLT Inhibitor and Biguanide Combinations, PTP1B Inhibitors and all other Oral Antidiabetic classes. Information Sources: Information has been sourced from both primary and secondary sources: Primary sources include industry surveys and face to face/telephone interviews with physicians and industry experts. Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases. Forecasting Methodology: IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast.

5 Table of Contents 1 Executive Summary Epidemiology Total Diabetes Patients Patients by Gender Patients by Age Group Market Dynamics Diabetes Market Current Trends ( ) Market Forecast ( ) Insulin Market Current Trends ( ) Market by Class Market by Molecule Top Players Top Drugs Market Forecast ( ) Oral Antidiabetics Current Trends ( ) Market by Class Top Players Top Drugs Market Forecast ( )

6 List of Figures Figure 2-1: Canada - Number of Diabetes Patients* (in 000 s), 2010, 2015, 2020, 2025 & Figure 2-2: Canada - Breakup of Diabetes Patients by Gender* (in 000 s), 2010, 2015, 2020, 2025 & Figure 2-3: Canada - Breakup of Diabetes Patients by Gender* (in %) 2010, 2015, 2020, 2025 & Figure 2-4: Canada - Breakup of Diabetes Patients* by Age Group (in 000 s), 2010, 2015, 2020, 2025 & Figure 2-5: Canada - Breakup of Diabetes Patients* by Age Group (in %) 2010, 2015, 2020, 2025 & Figure 3-1: Canada - Diabetes Market (in Million US$), Figure 3-2: Canada - Diabetes Market - Breakup of Insulin and Oral Antidiabetics (in %), Figure 3-3: Canada - Diabetes Market Forecast (in Million US$), Figure 3-4: Canada - Diabetes Market - Breakup of Insulin and Oral Antidiabetics (in %), Figure 3-5: Canada - Insulin Market (in Million US$), Figure 3-6: Canada - Insulin Market - Share by Class (in %), Figure 3-7: Canada - Insulin Market - Share by Molecules (in %), Figure 3-8: Canada - Insulin Market - Share of Key Players (in %), Figure 3-9: Canada - Insulin Market - Share of Key Drugs (in %), Figure 3-10: Canada - Insulin Market Forecast (in Million US$), Figure 3-11: Canada - Oral Antidiabetics Market, (in Million US$), Figure 3-12: Canada - Oral Antidiabetics Market - Share by Class (in %), Figure 3-13: Canada - Oral Antidiabetics Market - Share of Key Players (in %), Figure 3-14: Canada - Oral Antidiabetics Market - Share of Key Drugs (in %), Figure 3-15: Canada - Oral Antidiabetics Market Forecast (in Million US$), Figure 3-16: Canada - Oral Antidiabetics Market - Share Forecast by Class (%),

7 List of Tables Table 1-1: Canada - Oral Antidiabetics & Insulin Market Definitions... 8 Table 3-1: Canada - Insulin Market - Sales by Class (in Million US$), Table 3-2: Canada - Insulin Market - Sales by Molecule (in Million US$), Table 3-3: Canada - Insulin Market - Share of Key Players (in Million US$), Table 3-4: Canada - Insulin Market - Sales of Key Drugs (in Million US$), Table 3-5: Canada - Oral Antidiabetics Market - Sales by Class (in Million US$), Table 3-6: Canada - Oral Antidiabetics Market - Sales of Key Players (in Million US$), Table 3-7: Canada - Oral Antidiabetics Market - Sales of Key Drugs (in Million US$), Table 3-9: Canada - Oral Antidiabetics - Sales Forecast by Class, (in Million US$), 2010, 2013 & Table 3-8: Canada - Oral Antidiabetics Market - New Drug Launches ( )... 36

8 % Population in (000's) 2.3 Patients by Age Group The prevalence of diabetes has been found to increase with age. The proportion of people above 60 years of age in Canada has been increasing rapidly since the last few years and has been a major driver of diabetes in the Country. In 2010, approximately 52% of the diabetes patients in Canada were above 60 years of age and this proportion is expected to reach 65% by Figure 2-4: Canada - Breakup of Diabetes Patients* by Age Group (in 000 s), 2010, 2015, 2020, 2025 & ,000 2,500 2,000 1,500 1, Source: International Diabetes Federation & IMARC Group *Note: Age Figure 2-5: Canada - Breakup of Diabetes Patients* by Age Group (in %) 2010, 2015, 2020, 2025 & % 80% 60% 40% 20% 0% 52% 55% 58% 62% 65% 39% 36% 33% 31% 28% 8.6% 8.7% 8.4% 7.7% 6.6% Source: International Diabetes Federation & IMARC Group *Note: Age 20-79

9 Market by Class Biguanide Antidiabetics represented the largest Oral Antidiabetic class accounting for 34% of the total Oral Antidiabetics market in Sales of Glitazones witnessed a strong growth till In 2007, however, the FDA issued black box warnings against its two drugs i.e. Avandia and Actos which were found to induce heart attacks. This led to a decline in their uptake from 2008 onwards. DPP-IV Inhibitors have witnessed a strong uptake in their sales with the launch of Sitagliptin and Vidagliptin. This class accounted for around 11% of the total Oral Antidiabetics market in Table 3-5: Canada - Oral Antidiabetics Market - Sales by Class (in Million US$), Class Biguanide Antidiabetics Glitazone Antidiabetics Sulphonylurea Antidiabetics DPP-IV Inhibitor Antidiabetics Glitazone & Biguanide Antidiabetic Combinations Glinide Antidiabetics GLP-1 Agonist Antidiabetics DPP-IV Inhibitor & Biguanide Antidiabetic Combinations Alpha-Glucosidase Inhibitor Antidiabetics Other Drugs For Diabetes Glitazone & Sulphonylurea Antidiabetic Combinations Total Source: IMARC Group

10 % in Million US$ Figure 3-12: Canada - Oral Antidiabetics Market - Share by Class (in %), % 50.0% 40.0% % 20.0% 10.0% 0.0% Total Market Glitazone Antidiabetics DPP-IV Inhibitor Antidiabetics Glinide Antidiabetics Other Drugs For Diabetes Glitazone and Sulphonylurea Antidiabetic Combinations Biguanide Antidiabetics Sulphonylurea Antidiabetics Glitazone and Biguanide Antidiabetic Combinations Alpha-Glucosidase Inhibhitor Antidiabetics DPP-IV Inhibitor and Biguanide Antidiabetic Combinations GLP-1 Agonists Source: IMARC Group

11 2010 IMARC All Rights Reserved This Publication and all it s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.